Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides.
In this study (1998-1999), we collected 215 macrolide-resistant Streptococcus pneumoniae isolates from an ongoing Canadian Respiratory Organism Surveillance Study involving 23 centers representing all regions of Canada. The prevalence of erythromycin-resistant S. pneumoniae was 8% (215 of 2,688). Of the 215 isolates, 48.8% (105 of 215) were PCR positive for mef(A) and 46.5% (100 of 215) were PCR positive for erm(B). The ketolides telithromycin and ABT-773 demonstrated excellent activity against both mef(A) (MIC for 90% of strains [MIC(90)], 0.06 and 0.03 microg/ml, respectively) and erm(B) (MIC(90), 0.06 and 0.03 microg/ml, respectively) strains of S. pneumoniae.
Hoban
D J
DJ
Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Health Sciences Centre, Winnipeg, Manitoba, Canada.
Wierzbowski
A K
AK
Nichol
K
K
Zhanel
G G
GG
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001426:Bacterial Proteins; D002170:Canada; D004352:Drug Resistance, Microbial / Q000502:physiology; D004917:Erythromycin / Q000031:analogs & derivatives* / Q000494:pharmacology; D005787:Gene Frequency; D006801:Humans; D048628:Ketolides; D018942:Macrolides; D008565:Membrane Proteins / Q000032:analysis* / Q000235:genetics; D008780:Methyltransferases / Q000032:analysis* / Q000235:genetics; D008826:Microbial Sensitivity Tests; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D048628:Ketolides; D018942:Macrolides; C117866:MefA protein, Streptococcus; D008565:Membrane Proteins; D004917:Erythromycin; D008780:Methyltransferases; C035181:rRNA (adenosine-O-2'-)methyltransferase; C405499:cethromycin; C106791:telithromycin